InvestorsHub Logo
Followers 5
Posts 1109
Boards Moderated 0
Alias Born 05/02/2014

Re: RockoTaco post# 32413

Friday, 02/19/2016 6:32:51 AM

Friday, February 19, 2016 6:32:51 AM

Post# of 140477
My take on Alf has been that it was developed academically, by consortium, and also EU money. Marketing may not really have been ever addressed seriously. Probably too many opinions about whether the project was ready to fly and compete with daVinci. Strategically TRXC may have been very smart to present themselves a North American based "robotics upstart" who could handle that. Hence the low price paid by TRXC. I am sure hands from Sofar and other entities are still going to get kickback from any sales. I understand the entire Italian development team came along in the sale.
So, if Alf is any good and can be updated or modified to compete with ISRG, TRXC may have something to work with. However, my experience with niche, highly-specialized medical products from Europe is that the acceptance in the US is low. Of course I'm not speaking about Siemens, Phillips, Draeger, etc.. But I really wonder if TRXC has the experience and know-how to bring Alf into the US. It would be interesting if they could get things moving in Europe first. But that brings up a question: Why wouldn't a Phillips, or a Siemens have bought Alf?
That's why I think TRXC is probably all about hype, not substance.
Surgibot is already going to be a bust for them, Alf is a last-ditch get rich play.